Effective January 1, 2017 - New permanent J-code for ONIVYDE®: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-6225

HIT
PANCREATIC
CANCER
HEAD ON

ONIVYDE®

(irinotecan liposome injection)

The first and only therapy FDA-approved
in combination with 5-FU/LV for patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy1,2

  • PHYSICIAN VIDEOS &
    RESOURCES

    Clinical experts review the results of the NAPOLI-1 study

  • RECOMMENDED
    DOSING REGIMEN

    Review information about dosing and dose modifications for ONIVYDE®

  • IPSEN CARES®

    Learn more about coverage, access, reimbursement, and educational support for patients and caregivers.

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

References: 1. ONIVYDE® Full Prescribing Information. 2. Data on file. Basking Ridge, NJ; Ipsen Biopharmaceuticals, Inc.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION